AssetMark Inc’s CVS Health CVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$66.9M Sell
646,506
-81,789
-11% -$7.3M 0.12% 153
2026
Q1
$52.3M Sell
728,295
-4,374
-0.6% -$337K 0.11% 162
2025
Q4
$58.1M Buy
732,669
+54,111
+8% +$4.27M 0.12% 144
2025
Q3
$51.2M Buy
678,558
+75,603
+13% +$5.18M 0.11% 154
2025
Q2
$41.6M Buy
602,955
+69,152
+13% +$4.53M 0.1% 172
2025
Q1
$36.2M Buy
533,803
+147,655
+38% +$8.84M 0.1% 171
2024
Q4
$17.3M Sell
386,148
-23,853
-6% -$1.34M 0.05% 272
2024
Q3
$25.8M Buy
410,001
+36,132
+10% +$2.11M 0.07% 199
2024
Q2
$22.1M Buy
373,869
+131,223
+54% +$8.21M 0.07% 214
2024
Q1
$19.4M Buy
242,646
+6,174
+3% +$472K 0.06% 217
2023
Q4
$18.7M Sell
236,472
-1,407
-0.6% -$100K 0.07% 211
2023
Q3
$16.6M Sell
237,879
-1,080,102
-82% -$76.5M 0.07% 212
2023
Q2
$91.1M Sell
1,317,981
-480,323
-27% -$34.2M 0.36% 63
2023
Q1
$134M Buy
1,798,304
+25,893
+1% +$2.17M 0.55% 41
2022
Q4
$165M Buy
1,772,411
+50,376
+3% +$4.86M 0.72% 35
2022
Q3
$164M Buy
1,722,035
+70,764
+4% +$7M 0.77% 35
2022
Q2
$153M Buy
1,651,271
+6,420
+0.4% +$627K 0.69% 37
2022
Q1
$166M Sell
1,644,851
-89,097
-5% -$9.36M 0.7% 38
2021
Q4
$179M Buy
1,733,948
+1,201,430
+226% +$111M 0.73% 36
2021
Q3
$45.2M Buy
532,518
+18,033
+4% +$1.51M 0.2% 120
2021
Q2
$42.9M Sell
514,485
-115,324
-18% -$9.44M 0.2% 123
2021
Q1
$47.4M Sell
629,809
-9,057
-1% -$660K 0.24% 102
2020
Q4
$43.6M Buy
638,866
+36,973
+6% +$2.4M 0.24% 102
2020
Q3
$35.2M Buy
601,893
+359,181
+148% +$22.3M 0.23% 108
2020
Q2
$15.5M Buy
242,712
+232,684
+2,320% +$14.7M 0.11% 162
2020
Q1
$595K Buy
10,028
+4,477
+81% +$299K 0.01% 368
2019
Q4
$412K Sell
5,551
-5,171
-48% -$363K ﹤0.01% 428
2019
Q3
$676K Sell
10,722
-138,662
-93% -$8.22M 0.01% 348
2019
Q2
$8.14M Buy
149,384
+51,229
+52% +$2.76M 0.07% 195
2019
Q1
$5.29M Buy
98,155
+70,882
+260% +$4.37M 0.05% 213
2018
Q4
$1.79M Buy
27,273
+21,954
+413% +$1.64M 0.02% 252
2018
Q3
$419K Buy
5,319
+665
+14% +$47.5K ﹤0.01% 376
2018
Q2
$300K Sell
4,654
-1,186
-20% -$78.2K ﹤0.01% 394
2018
Q1
$363K Sell
5,840
-797
-12% -$57.2K ﹤0.01% 374
2017
Q4
$481K Buy
6,637
+150
+2% +$10.9K 0.01% 364
2017
Q3
$528K Sell
6,487
-8,133
-56% -$643K 0.01% 349
2017
Q2
$1.18M Sell
14,620
-1,155
-7% -$91.2K 0.01% 274
2017
Q1
$1.24M Sell
15,775
-260
-2% -$20.8K 0.02% 270
2016
Q4
$1.26M Sell
16,035
-1,230
-7% -$99.5K 0.02% 252
2016
Q3
$1.54M Buy
17,265
+4
+0% +$378 0.02% 229
2016
Q2
$1.65M Sell
17,261
-5,360
-24% -$534K 0.03% 229
2016
Q1
$2.35M Sell
22,621
-907
-4% -$88.2K 0.04% 204
2015
Q4
$2.3M Buy
23,528
+11,920
+103% +$1.17M 0.04% 201
2015
Q3
$1.12M Sell
11,608
-24,585
-68% -$2.58M 0.02% 226
2015
Q2
$3.8M Buy
36,193
+2,811
+8% +$287K 0.08% 119
2015
Q1
$3.44M Buy
33,382
+1,680
+5% +$170K 0.07% 119
2014
Q4
$3.05M Buy
31,702
+1,545
+5% +$136K 0.07% 141
2014
Q3
$2.4M Buy
30,157
+157
+0.5% +$12.4K 0.06% 166
2014
Q2
$2.26M Sell
30,000
-203
-0.7% -$15.3K 0.05% 173
2014
Q1
$2.26M Sell
30,203
-754
-2% -$53.3K 0.06% 142
2013
Q4
$2.22M Sell
30,957
-845
-3% -$54.3K 0.05% 160
2013
Q3
$1.8M Buy
+31,802
New +$1.9M 0.05% 185

Other funds holding CVS

AssetMark Inc's CVS Position: Q2 2026 in Review

AssetMark Inc reduced its CVS Health (CVS) stake by 11% in Q2 2026, selling an estimated $7.3M and leaving 646,506 shares worth $66.9M. The position accounts for 0.12% of the portfolio, ranked #153.

AssetMark Inc first reported a position in CVS in Q3 2013 and has held it in 52 quarters since. The position peaked at $179M in Q4 2021. 2,061 funds tracked by Wall St. Rank hold CVS as of Q2 2026.

  • AssetMark Inc held 646,506 shares of CVS Health worth $66.9M as of Q2 2026.
  • AssetMark Inc sold 81,789 CVS Health shares in Q2 2026, an estimated $7.3M.
  • CVS Health made up 0.12% of AssetMark Inc's portfolio in Q2 2026, its #153 holding.
  • AssetMark Inc first reported a position in CVS Health in Q3 2013 and has held it in 52 quarters since.
  • AssetMark Inc's CVS Health position peaked at $179M in Q4 2021.
  • 2,061 funds tracked by Wall St. Rank held CVS Health as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.